Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.36 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | XBP1 | P17861 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18342541 | 1.00 | CA12 (0.41) | CA12CA14DGAT1CA1CA2 | |
| Hydrochloric Acid SCHEMBL31645354 | 1.00 | CA12 (0.41) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3725616 | 0.98 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3728417 | 0.98 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3725618 | 0.98 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL30902877 | 0.88 | CA12 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL5801336 | 0.86 | CA14 (0.46) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL13223287 | 0.84 | CA12 (0.37) | CA12CA14DGAT1CA1CA2 | |
| Hydrochloric Acid SCHEMBL18281363 | 0.80 | CA12 (0.40) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3185669 | 0.79 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719602-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. | 2025-10-09 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| EP-4525873-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | Biomea Fusion, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024249517-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-19 | — | — | US | disclosed |
| CN-118829631-A | Pyrazine compounds as FLT3 inhibitors | 拜欧米富士恩公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-112601553-A | Binder-drug conjugates against CXCR5 with enzymatically cleavable linkers and improved activity profile | 拜耳股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3784669-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112218865-A | Pteridinone compounds and uses thereof | 沃泰克斯药物股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20190328897-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
| CN-110312534-A | Antibody-drug-conjugates (ADC) with enzymatically cleavable groups | 拜耳制药股份公司 | 2019-10-08 | — | — | CN | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| CN-108025084-A | Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups | 拜耳医药股份有限公司 | 2018-05-11 | — | — | CN | disclosed |
| EP-1732924-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005095395-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | CA2 4239/4885GAA 1496/4885CA12 4586/4885 |
| US-20190328897-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | VCAM1, FCGR1A, DNPEP | CA2 1608/4885GAA 17/4885CA12 456/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | CA2 4030/4885GAA 2063/4885CA12 4350/4885 |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | CCR5, CD4, NFATC1 | CA2 4208/4885GAA 422/4885CA12 4488/4885 |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | CA2 2240/4885GAA 578/4885CA12 2544/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | CA2 3949/4885GAA 2486/4885CA12 4482/4885 |
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | FLT3, MEN1, FEM1B | CA2 4512/4885GAA 2907/4885CA12 4646/4885 |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | CA2 2915/4885GAA 382/4885CA12 2886/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | CA2 4030/4885GAA 2063/4885CA12 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.